Atara Submits BLA for Cell Therapy for Post-Transplant Complication.

The article details Atara Biotherapeutics' submission of a biologics license application to the FDA for tabelecleucel (tab-cel) as a treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Topics include the significant need for a targeted therapy for EBV+ PTLD, tab-cel's efficacy and safety data from clinical studies, and the financial and marketing arrangements between Atara and Pierre Fabre Laboratories.